Xenical Pediatric AERs Need Continued Monitoring, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Pediatric adverse events associated with Roche's Xenical (orlistat) could be a concern for FDA when an attempt is made to switch the drug over the counter
You may also be interested in...
Xenical Adolescent Safety, Efficacy Needs Further Study – JAMA Editorial
More research is needed on Xenical (orlistat) therapy for adolescent weight loss, according to an editorial in the June 15 Journal of the American Medical Association
Xenical Adolescent Safety, Efficacy Needs Further Study – JAMA Editorial
More research is needed on Xenical (orlistat) therapy for adolescent weight loss, according to an editorial in the June 15 Journal of the American Medical Association
Xenical Adolescent Safety, Efficacy Needs Further Study – JAMA Editorial
More research is needed on Xenical (orlistat) therapy for adolescent weight loss, according to an editorial in the June 15 Journal of the American Medical Association